Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
07/2003
07/17/2003WO2003057698A2 Spiroazacyclic compounds as monoamine receptor modulators
07/17/2003WO2003057696A1 Deazapurines and uses thereof
07/17/2003WO2003057691A1 Process and intermediates for pyridazinone antidiabetic agents
07/17/2003WO2003057690A1 Indolinone derivatives useful as protein kinase inhibitors
07/17/2003WO2003057688A2 Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators
07/17/2003WO2003057685A1 Luminacin analogs and uses thereof
07/17/2003WO2003057676A1 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists
07/17/2003WO2003057673A1 1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
07/17/2003WO2003057668A1 Nitrogenous cyclic ketone derivative, process for producing the same, and use
07/17/2003WO2003057666A2 Inhibitors of dipeptidyl peptidase iv
07/17/2003WO2003057664A1 Carboxamidine derivatives and their use in the treatment of vascular diseases
07/17/2003WO2003057380A2 Compositions including ammonia oxidizing bacteria and methods of using same
07/17/2003WO2003057252A1 Human mast cell-expressed membrane proteins
07/17/2003WO2003057245A1 Compositions for improving lipid metabolism
07/17/2003WO2003057242A1 Use of erythropoietin for the preventive or curative treatment of cardiac failure
07/17/2003WO2003057224A1 Apoptosis inductor
07/17/2003WO2003057222A1 Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor
07/17/2003WO2003057220A1 Cyclic urea derivatives with 5-ht2c receptor activity
07/17/2003WO2003057219A1 Aroyl pyrrole heteroeryl and methanols useful for treating a central nervous system disorder
07/17/2003WO2003057218A1 Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof
07/17/2003WO2003057216A1 Pharmaceutical composition comprising a glitazone and a 4-oxobutanoic acid, and the use thereof for treating diabetes
07/17/2003WO2003057211A1 Composition inhibiting matrix-metallproteinases for the treatmentof neoplastic diseases.
07/17/2003WO2003057205A2 Combination of mtp inhibitors or apob secretion inhibitors with fibrates for use as drugs
07/17/2003WO2003057203A2 Biomaterials based on hyaluronic acid for the anti-angiogenic therapy in the treatment of tumours
07/17/2003WO2003057200A2 Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes
07/17/2003WO2003057196A1 Drug mixture with enhanced dissolution rate
07/17/2003WO2003057195A1 Pravastatin pharmaceutical formulations and methods of their use
07/17/2003WO2003057170A2 Oral insulin therapy
07/17/2003WO2003057169A2 4-dedimethylamino tetracycline compounds
07/17/2003WO2003057166A2 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
07/17/2003WO2003057148A2 Use of biomolecular targets in the treatment and visualization of tumors
07/17/2003WO2003057147A2 Useful aroyl pyrrole heteroaryl methanones and methanols
07/17/2003WO2003057144A2 Change inhibitors of dipeptidyl peptidase iv
07/17/2003WO2003057134A2 Specific binding agents of human angiopoietin-2
07/17/2003WO2003056899A2 Nitric oxide donors for treatment of disease and injury
07/17/2003WO2003035838A3 Stem cells that transform to beating cardiomyocytes
07/17/2003WO2003030827A3 Compositions for and methods of treating and preventing sirs/sepsis
07/17/2003WO2003022809A3 Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
07/17/2003WO2003020325A3 Methods for sterilizing preparations containing albumin
07/17/2003WO2003000896A3 POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-5 GENE
07/17/2003WO2002081684A3 Antisense calpain nucleotides and uses thereof
07/17/2003WO2002067938A3 Treating or reducing the risk of cardiovascular disease
07/17/2003WO2002059286A3 Adenylate cyclases
07/17/2003WO2002057450A3 Proteins and nucleic acids encoding same
07/17/2003WO2002055693A3 Method for inhibiting the expression of a target gene
07/17/2003WO2002055496A8 Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
07/17/2003WO2002055495A8 Aryl piperidine derivatives as inducers of ldl-receptor expression
07/17/2003WO2002040683A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
07/17/2003WO2002031134A3 Novel serine protease genes related to dppiv
07/17/2003WO2002009723A3 Ammonium salts of hemoglobin allosteric effectors, and uses thereof
07/17/2003US20030135113 Method of drug delivery to interstitial regions of the myocardium
07/17/2003US20030135055 Inhibitors of factors Xa and VIIa
07/17/2003US20030135045 Glycoprotein IIb/IIIa antagonists
07/17/2003US20030135044 Novel gamma secretase inhibitors
07/17/2003US20030134902 Novel dicarboxylic acid derivatives
07/17/2003US20030134901 Lipoxin compounds and their use in treating cell proliferative disorders
07/17/2003US20030134888 Substituted diaminopyrazoles; treating diseases, such as cancer, inflammatory disorders, restenosis, and cardiovascular disease. coatings for implantable medical devices, such as prostheses, artificial valves, etc.
07/17/2003US20030134886 Pharmaceutically active compounds
07/17/2003US20030134884 Benzyloxyiminohydrocarbylcarboxy compounds, such as E-4-(4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyloxyimino)--4-phenylbutyric acid
07/17/2003US20030134882 Use of C2-substituted indan-1-one systems for preparing medicaments for the prophylaxis or treatment of obesity
07/17/2003US20030134879 Substituted with a thio, sulfoxy or sulfonyl group
07/17/2003US20030134874 Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
07/17/2003US20030134873 8-phenyl-(1,2,4)triazolo(1,5-a)pyridin-2-yl)-benzamide derivatives
07/17/2003US20030134872 2-acetoxy-5-(alpha-cyclopropylcarbonyl-O-fluorobenzyl)--4,5,6,7 -tetrahydrothieno(3,2-c)-pyridine, particularly the hydrochloride and the maleate
07/17/2003US20030134861 Transmucosal phosphodiesterase inhibitors for the treatment of erectile dysfunction
07/17/2003US20030134859 Substituted 2-chloro-5-nitrobenzamides; treating retrograde osteoporosis and diabetes mellitus
07/17/2003US20030134858 Treatment of inflammation associated disorders, such as arthritis, colon cancer, and Alzheimer's disease
07/17/2003US20030134856 Method and structure for inhibiting activity of serine elastases
07/17/2003US20030134855 P-acylaminomethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2 -yl)-benzamides; treatment of diseases related to the adenosine receptor, such as Alzheimer's disease, depression, drug addiction, Parkinson's and ADHD
07/17/2003US20030134854 Treatment of diseases related to the adenosine receptor, such as Alzheimer's disease, depression, drug addiction, neuroprotection, Parkinson's disease, and attention deficit hyperactivity disorder.
07/17/2003US20030134850 Hydrazinyl and nitrogen oxide pyrazoles
07/17/2003US20030134849 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors
07/17/2003US20030134848 Substituted 1-aza-2-imino-heterocycles and their use as nicotinic acetylcholin receptors activators
07/17/2003US20030134847 New polycyclic azaindole compounds
07/17/2003US20030134840 Novel compounds
07/17/2003US20030134839 5-(Alkylidene-cycloalkyl)-and 5-(alkylidene-heterocyclyl)-pyrazoles
07/17/2003US20030134836 Substituted arylamine derivatives and methods of use
07/17/2003US20030134829 X is a ring having at least 4 atoms in the ring; K is hydrocarbyl group; Rh1 is an optional halo group; Rh2 is an optional halo group; at least one of Rh1 and Rh2 is present; Rs is any one of a sulphamate group, a phosphonate,
07/17/2003US20030134810 Delivery of pharmacologically active agents associated with polymeric biocompatible materials. Compositions comprising a first, negatively charged pharmacologically active agent such as an oligonucleotide and a polycationic polymer such as
07/17/2003US20030134801 Pharmaceutical compositions containing them are of the class of thrombin inhibitors which are useful as anticoagulants.
07/17/2003US20030134796 Antithrombin for the prevention and therapy of vasculoproliferative disorders
07/17/2003US20030134777 Treating or preventing arrhythmias in a human subject comprising the administration of an effective amount of a calcium/calmodulin-dependent protein kinase inhibitor. Also provided are pharmaceutical compositions as antiarrhythmia
07/17/2003US20030134430 Novel amino acid sequences for human caenorhabditis elegans-like protein polypeptides
07/17/2003US20030134387 Vertebrate globin
07/17/2003US20030134319 Amino acid sequences of peptides that are encoded by genes within the human genome, the kinase peptides
07/17/2003US20030134282 Quantitative analysis of tissue gene expression; amplification; polymerase chain reaction
07/17/2003US20030133992 Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
07/17/2003US20030133930 Administering to a patient having an autoimmune disorder an antibody to a B-cell antigens and a carrier; CD22, CD20, CD19, and CD74 or HLA-DR antigen.
07/17/2003US20030131844 Inducing hypothermia and rewarming using a helium-oxygen mixture
07/17/2003CA2767061A1 Specific binding agents of human angiopoietin-2
07/17/2003CA2473106A1 Pravastatin pharmaceutical formulations and methods of their use
07/17/2003CA2473097A1 Compositions including ammonia oxidizing bacteria and methods of using same
07/17/2003CA2473043A1 Pharmaceutical composition comprising a glitazone and a 4-oxobutanoic acid, and the use thereof for treating diabetes
07/17/2003CA2472585A1 Drug mixture with enhanced dissolution rate
07/17/2003CA2472331A1 Process and intermediates for pyridazinone antidiabetic agents
07/17/2003CA2472198A1 Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof
07/17/2003CA2472165A1 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists
07/17/2003CA2472111A1 Human mast cell-expressed membrane proteins
07/17/2003CA2472049A1 Dominant negative proteins and methods thereof
07/17/2003CA2471951A1 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
1 ... 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 ... 1595